- Tytuł:
- 125MO Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
- Autorzy:
- Źródło:
- In ESMO Open May 2023 8(1) Supplement 4
Czasopismo naukowe